Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

× No keyword cloud information.

12 in total

Review 1. Investigational agents in development for the treatment of ovarian cancer.

Authors: Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal: Invest New Drugs Date: 2012-06-04 Impact factor: 3.850

2. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?

Authors: Cristiana Sessa; Gianluca Del Conte
Journal: Nat Rev Clin Oncol Date: 2010-02 Impact factor: 66.675

3. Recent progress in the diagnosis and treatment of ovarian cancer.

Authors: Danijela Jelovac; Deborah K Armstrong
Journal: CA Cancer J Clin Date: 2011-04-26 Impact factor: 508.702

4. Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Authors: Monica Binaschi; Cecilia Simonelli; Cristina Goso; Mario Bigioni; Carlo Alberto Maggi
Journal: Exp Ther Med Date: 2011-01-14 Impact factor: 2.447

5. Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.

Authors: Motohiro Tamiya; Hidekazu Suzuki; Takayuki Shiroyama; Ayako Tanaka; Naoko Morishita; Norio Okamoto; Kenichi Sakai; Hironori Shigeoka; Kunimitsu Kawahara; Tomonori Hirashima
Journal: Invest New Drugs Date: 2018-03-14 Impact factor: 3.850

6. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Authors: Kae Hashimoto; Shan Man; Ping Xu; William Cruz-Munoz; Terence Tang; Rakesh Kumar; Robert S Kerbel
Journal: Mol Cancer Ther Date: 2010-04-06 Impact factor: 6.261

Review 7. Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors: Timothy A Yap; Craig P Carden; Stan B Kaye
Journal: Nat Rev Cancer Date: 2009-03 Impact factor: 60.716

8. OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.

Authors: Marek Malecki; Raf Malecki
Journal: Proc S Dak Acad Sci Date: 2008

Review 9. The role of antiangiogenesis therapy: bevacizumab and beyond.

Authors: Hernán Cortés-Funes
Journal: Clin Transl Oncol Date: 2009-06 Impact factor: 3.405

10. Bevacizumab for the Treatment of Non-Resectable Pseudomyxoma peritonei Associated with Mucinous Ovarian Tumor of Low Malignant Potential - A Comparison of Two Cases.

Authors: Ira Winer; Ronald J Buckanovich
Journal: Case Rep Oncol Date: 2009-01-12